GlaxoSmithKline Starts 2 Phase III Studies In Advanced/Metastatic Melanoma
LONDON (Dow Jones)--GlaxoSmithKline (GSK.LN), the drug giant, Monday announced the start of two global Phase III studies in advanced or metastatic melanoma patients with a BRAF V600 mutation.
The studies will separately assess the efficacy and safety of two investigational agents, GSK2118436 and GSK1120212, to determine their individual ability to stop or slow the progression of skin cancer in patients whose tumours contain a BRAF V600 mutation, which occurs in 50 to 60 percent of melanoma patients.
Commencement of these studies confirms previously announced plans to progress these assets into Phase III.
Shares at 1305 GMT up 1.34% at 1171.50 pence valuing the company at GBP60.87 billion.
Jan 25, 2011